Taken together, it follows that nutrient-sensing receptors could be therapeutic targets and their agonism a potent strategy that enhances insulin signaling, energy homeostasis and intestinal function, highlighting the significance of dietary microbiota-accessible carbohydrates (61) and the development of new agonists for the treatment of metabolic diseases. The gene discussed is INS; the disease is metabolic disease.